An antiemetic is a pharmacological agent that inhibits or prevents nausea and vomiting. These substances are employed in the treatment and prophylaxis of emesis arising from a variety of causes, including postoperative recovery, chemotherapy, radiation therapy, motion sickness, gastrointestinal disorders, and certain metabolic disturbances.
Classification
Antiemetics are categorized according to their primary mechanism of action and the receptors they target:
| Class | Principal Mechanism | Representative Drugs |
|---|---|---|
| Serotonin (5‑HT₃) receptor antagonists | Block 5‑HT₃ receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract | Ondansetron, granisetron, palonosetron |
| Dopamine (D₂) receptor antagonists | Inhibit D₂ receptors in the CTZ | Metoclopramide, prochlorperazine, haloperidol |
| Neurokinin‑1 (NK₁) receptor antagonists | Block substance P binding to NK₁ receptors in the vomiting center | Aprepitant, fosaprepitant, netupitant |
| Antihistamines (H₁) | Antagonize H₁ receptors, also possessing anticholinergic activity | Dimenhydrinate, diphenhydramine, meclizine |
| Anticholinergics (muscarinic) | Block muscarinic receptors in the vestibular apparatus | Scopolamine |
| Cannabinoids | Activate cannabinoid receptors (CB₁) influencing emetic pathways | Dronabinol, nabilone |
| Others | Diverse mechanisms, e.g., glucocorticoids modulate inflammatory mediators; ginger constituents affect gastrointestinal motility | Dexamethasone, ginger (Zingiber officinale) extracts |
Mechanistic Overview
Nausea and vomiting are coordinated by the central vomiting center in the medulla oblongata, which integrates input from the gastrointestinal tract, vestibular system, chemoreceptor trigger zone, and higher cortical centers. Antiemetics act by interrupting these pathways at peripheral or central sites, thereby reducing the likelihood of the emetic response.
Clinical Applications
- Chemotherapy‑induced nausea and vomiting (CINV): Combination regimens (e.g., a 5‑HT₃ antagonist + NK₁ antagonist + dexamethasone) are standard prophylaxis for moderately and highly emetogenic chemotherapy.
- Postoperative nausea and vomiting (PONV): Single‑agent or multimodal prophylaxis, often utilizing a 5‑HT₃ antagonist or a combination of a dopamine antagonist with a corticosteroid.
- Radiation‑induced emesis: Similar agents to CINV are employed, with dosing adjusted for radiation schedules.
- Motion sickness: Primarily antihistamines and anticholinergics are effective.
- Gastrointestinal disorders: Metoclopramide and domperidone, which also possess pro‑kinetic properties, are used for gastroparesis‑related nausea.
Adverse Effects
The safety profile varies by class. Common adverse events include:
- 5‑HT₃ antagonists: Headache, constipation, transient elevation of liver enzymes.
- D₂ antagonists: Extrapyramidal symptoms (e.g., dystonia, akathisia), sedation, hyperprolactinemia.
- NK₁ antagonists: Fatigue, hiccups, potential drug‑interaction via CYP3A4 metabolism.
- Antihistamines/anticholinergics: Drowsiness, dry mouth, blurred vision, urinary retention.
- Cannabinoids: Euphoria, dizziness, cognitive impairment.
Regulatory Status
Most antiemetic agents are approved by major regulatory authorities (e.g., U.S. Food and Drug Administration, European Medicines Agency) for specific indications, often requiring prescription. Over‑the‑counter formulations are available for mild motion‑sickness prophylaxis (e.g., dimenhydrinate).
Historical Notes
Early antiemetic therapy relied on non‑specific agents such as phenothiazines (e.g., chlorpromazine) discovered in the 1950s. The introduction of selective 5‑HT₃ antagonists in the late 1980s markedly improved control of CINV, followed by NK₁ antagonists in the late 1990s, expanding therapeutic options.
Research Directions
Current investigational efforts focus on novel receptor targets (e.g., orexin receptors), personalized antiemetic regimens based on genetic polymorphisms affecting drug metabolism, and non‑pharmacologic modalities such as acupuncture and neurostimulation.
References
(References are omitted in this summary but would typically include peer‑reviewed pharmacology textbooks, clinical guideline documents, and FDA product labeling.)